HC Wainwright reaffirmed their buy rating on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Free Report) in a report issued on Thursday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.
Armata Pharmaceuticals Trading Up 1.5 %
NYSEAMERICAN:ARMP traded up $0.03 during mid-day trading on Thursday, hitting $1.98. 20,460 shares of the company's stock traded hands, compared to its average volume of 12,239. The company has a market capitalization of $71.64 million, a P/E ratio of -1.21 and a beta of 0.78. Armata Pharmaceuticals has a 1 year low of $1.89 and a 1 year high of $4.48.
About Armata Pharmaceuticals
(
Get Free Report)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Stories
Before you consider Armata Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.
While Armata Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
